First Western Ship Transits Strait of Hormuz Since Iran War Began 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Britain Courts Anthropic Amid US Defense Department Dispute 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
 - EconoTimes)
NEW YORK, Nov. 21, 2016 -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Dynavax Technologies Corporation (“Dynavax” or the “Company”) (Nasdaq:DVAX) in the United States District Court for the Northern District of California on behalf of purchasers of common stock of Dynavax between March 10, 2014 through November 11, 2016 (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the Securities Exchange Act of 1934.
Pursuant to the Complaint, Defendants made false and/or misleading statements and/or failed to disclose that: (1) there were significant adverse events associated with Dynavax’s HEPLISAV-B product, including an imbalance in the number of cardiac events during use; (2) consequently, a commercial product launch of HEPLISAV-B was less imminent than Dynavax had led investors to believe; and (3) as a result, Dynavax’s public statements were materially false and misleading at all relevant times.
On April 15, 2014, the Company announced the initiation of a new Phase 3 clinical trial of HEPLISAV-B (known as HBV-23). The Company further stated that this safety and immunogenicity study was designed to address the Complete Response Letter regarding the HEPLISAV-B Biologics License Application that was issued to the Company by the U.S. Food and Drug Administration (“FDA”) in February, 2013. This study is intended to significantly increase the number of vaccinated subjects and provide a sufficiently-sized safety database for the FDA to make a final determination regarding the safety and immunogenicity of the product.
On November 14, 2016, the Company announced it had received a complete response letter (“CRL”) from the FDA, requesting additional information on the Company’s HEPLISAV-B product in connection with its Biologics License Application. On this news, the Company’s share price fell $7.50, or 64.65%, to close at $4.10 on November 14, 2016.
If you wish to serve as lead plaintiff, you must move the Court no later than January 17, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, or to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].
Please visit our website at http://www.gme-law.com for more information about the firm.
